Evidence map›Paper›PMID 31655007›Full record

ReviewAnnals of the New York Academy of Sciences2020

Adult stem cells and regenerative medicine-a symposium report.

Jennifer Cable, Elaine Fuchs, Irving Weissman, Heinrich Jasper, David Glass, Thomas A Rando, Helen Blau, Shawon Debnath, Anthony Oliva, Sangbum Park and 3 more

Abstract readReview
In one paragraph

Review in Annals of the New York Academy of Sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. mTORC1 regulates the proliferation of SOX9Histochemistry and cell biology · 2025
    Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jennifer CableScience Writer, New York, New York.
Elaine FuchsRobin Chemers Neustein Laboratory of Mammalian Cell Biology and Development, Howard Hughes Medical Institute, The Rockefeller University, New York, New York.
Irving WeissmanPathology Stem Cell Institute, Stanford University, Stanford, California.
Heinrich JasperGenentech, San Francisco, California.
David GlassNovartis, Cambridge, Massachusetts.
Thomas A RandoNeurology & Neurological Sciences, Stanford University, Stanford, California.
Helen BlauMicrobiology and Immunology - Baxter Labs, Stanford University, Stanford, California.
Shawon DebnathDepartment of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York.
Anthony OlivaLongeveron, Miami, Florida.
Sangbum ParkDepartment of Genetics, Yale University, New Haven, Connecticut.
Emmanuelle PasseguéColumbia Stem Cell Initiative, Department of Genetics & Development, Columbia University, New York, New York.
Carla KimDana Farber/Harvard Cancer Center, Boston, Massachusetts.
Mark A KrasnowDepartment of Biochemistry, Stanford University, Stanford, California.

Funding

Technology Development P2CHD086843 · NICHD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI AMBROSIO, FABRISIA · 2015 to 2024
$10.5M
Leveraging an ongoing longitudinal study of influenza vaccination to define immune signatures of response and risk of infection in older adults >75U01AI165826 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Sean Xiao Leng · 2022 to 2026
$8.2M
Cell Based Therapy for Non-Ischemic Dilated CardiomyopathyUM1HL113460 · NHLBI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI HARE, JOSHUA M · 2012 to 2018
$4.3M
A Phase 2b Clinical Trial to Study the Efficacy of Longeveron Mesenchymal Stem Cells (LMSCs) to Treat Aging FrailtyR44AG062015 · NIA · LONGEVERON, LLC · PI HARE, JOSHUA M, OLIVA, ANTHONY ANDREW · 2018 to 2020
$4.2M
Molecular Regulation of Stem Cell QuiescenceR01AR073248 · NIAMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RANDO, THOMAS A. · 2018 to 2022
$2.6M
Complement Components as Mediators of Cell and Tissue AgingR01AG055755 · NIA · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI RANDO, THOMAS A. · 2017 to 2021
$2.2M
Modulation of Bone Formation by SHN3DP5OD021351 · OD · WEILL MEDICAL COLL OF CORNELL UNIV · PI GREENBLATT, MATTHEW BLAKE · 2015 to 2019
$2.1M
Signaling pathways in lung stem cell differentiationR01HL125821 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KIM, CARLA F. · 2015 to 2018
$1.8M
Mechanisms of Thrombospondin-1 as a pulmonary vascular mediatorR01HL132266 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KIM, CARLA F. · 2017 to 2020
$1.6M
A Randomized, Blinded, Placebo-Controlled Clinical Trial to Evaluate Longeveron Mesenchymal Stem Cell (LMSC) Therapy for Treating The Metabolic SyndromeR42AG054322 · NIA · LONGEVERON, LLC · PI HARE, JOSHUA M, LENG, SEAN XIAO · 2017 to 2020
$1.1M
Muscle Stem Cell Therapy for Volumetric Muscle LossI01RX001222 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI HUANG, NGAN F. · 2014 to 2023
–
NHLBI NIH HHS R01 HL125821NHLBI NIH HHS R01 HL132266NHLBI NIH HHS UM1 HL113460NIAID NIH HHS U01 AI165826NIAMS NIH HHS R01 AR073248NIA NIH HHS R01 AG055755NIA NIH HHS R42 AG054322NIA NIH HHS R44 AG062015NICHD NIH HHS P2C HD086843NIH HHS DP5 OD021351RRD VA I01 RX001222
6 · The paper itself

Abstract

Adult stem cells are rare, undifferentiated cells found in all tissues of the body. Although normally kept in a quiescent, nondividing state, these cells can proliferate and differentiate to replace naturally dying cells within their tissue and to repair its wounds in response to injury. Due to their proliferative nature and ability to regenerate tissue, adult stem cells have the potential to treat a variety of degenerative diseases as well as aging. In addition, since stem cells are often thought to be the source of malignant tumors, understanding the mechanisms that keep their proliferative abilities in check can pave the way for new cancer therapies. While adult stem cells have had limited practical and clinical applications to date, several clinical trials of stem cell-based therapies are underway. This report details recent research presented at the New York Academy of Sciences on March 14, 2019 on understanding the factors that regulate stem cell activity and differentiation, with the hope of translating these findings into the clinic.

Indexed as

AdultAdult Stem CellsAgingAnimalsCell DifferentiationHumansNeoplasmsNew York CityRegenerative MedicineResearch ReportStem Cell Transplantationadult stem cellsage-related degenerationagingdifferentiationepidermal stem cellshematopoietic stem cellsimmune-stem cell interactionsinflammationlung stem cellsmesenchymal cellsmuscle stem cellsregenerative medicinestem cell nichestem cell signalingtissue regenerationtumor stem cells

Identifiers

PMID31655007
PMCPMC7135961

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.